A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Bristol-Myers Squibb
EMD Serono
Frontier Medicines Corporation
Filamon LTD
NeoImmuneTech
Sichuan Enray Pharmaceutical Sciences Company
A2 Biotherapeutics Inc.
AstraZeneca
Arvinas Inc.
Tasca Therapeutics
Essen Biotech
MBrace Therapeutics
Revolution Medicines, Inc.
Auricula Biosciences Inc.
Takeda
Second Life Therapeutics
Tyligand Pharmaceuticals (Suzhou) Limited
VM Oncology, LLC
Revolution Medicines, Inc.
Alaunos Therapeutics
Incyte Corporation
Eli Lilly and Company
LigaChem Biosciences, Inc.
GI Innovation, Inc.
TCR2 Therapeutics
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Cancer Research UK
Shanghai Public Health Clinical Center
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
A2 Biotherapeutics Inc.
Kymab Limited
Intensity Therapeutics, Inc.
Cybrexa Therapeutics
Purple Biotech Ltd.
Cyteir Therapeutics, Inc.
Coherent Biopharma (Hefei) Co., Ltd.
CytosinLab Therapeutics Co., Ltd.
NantCell, Inc.
Cancer Research UK
Chongqing Precision Biotech Co., Ltd
NantCell, Inc.
Second Affiliated Hospital of Guangzhou Medical University
Gritstone bio, Inc.
Klus Pharma Inc.
Genmab